Intelligence Profile
Research Papers
The available research on follistatin 344 consists primarily of preclinical studies and safety reports, with no formal clinical trials identified in major databases.
Preclinical Research
The most substantial evidence comes from animal studies examining follistatin's effects on muscle mass. A 2017 study published in Transgenic Research demonstrated that transgenic expression of human follistatin-344 increased skeletal muscle mass in pigs, suggesting potential therapeutic applications for muscle-wasting conditions.
Earlier preclinical work from 2013 in The Journal of Pharmacology and Experimental Therapeutics investigated an engineered human follistatin variant, providing insights into the pharmacokinetic and pharmacodynamic properties of modified follistatin molecules and their potential therapeutic applications.
Safety Concerns and Clinical Reports
Several publications have documented safety concerns with follistatin 344 use. A 2020 retrospective case series published in International Ophthalmology reported cases of central serous chorioretinopathy (a retinal condition) associated with high-dose follistatin-344 use, though the study design and sample size were not specified in the available abstracts.
Regulatory and Quality Issues
Multiple reports from 2019-2020 in Drug Testing and Analysis focused on detection methods for black market follistatin 344, highlighting concerns about unregulated products and quality control in non-pharmaceutical sources.
Disease Association Research
A 2025 study in the International Journal of Molecular Sciences examined the relationship between high serum follistatin levels and impaired physical function in rheumatoid arthritis patients, though this investigated endogenous follistatin rather than therapeutic administration.
Review Literature
A 2026 review in Sports Medicine addressed the safety and efficacy of both approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, likely including follistatin 344 among other compounds.
Important Note: The absence of formal clinical trials and the reliance on case reports and preclinical data indicates that evidence for follistatin 344's safety and efficacy in humans remains limited. This content is for informational purposes only and should not be considered medical advice.